Myelin-associated proteins are potential diagnostic markers in patients with primary brain tumour

References

• Westphal M, Lamszus K. Circulating biomarkers for gliomas. Nat Rev Neurol. 2015;11(10):556–566.
   PubMed Web of Science ®Google Scholar
• Albulescu R, Codrici E, Popescu ID, et al. Cytokine patterns in brain tumour progression. Mediators Inflamm. 2013;2013:979747–979748.
   Web of Science ®Google Scholar
• Kros JM, Mustafa DM, Dekker LJM, et al. Circulating glioma biomarkers. Neuro Oncol. 2015;17(3):343–360.
   PubMed Web of Science ®Google Scholar
• Hochberg FH, Atai NA, Gonda D, et al. Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. Expert Rev Mol Diagn. 2014;14(4):439–452.
   PubMed Web of Science ®Google Scholar
• Qin X, Kang L, Liu Y, et al. Chinese medicine's intervention effect on Nogo-A/NgR. Evid Based Complement Alternat Med. 2012; 2012:528482–528484.
   PubMed Web of Science ®Google Scholar
• McKerracher L, Rosen KM. MAG, myelin and overcoming growth inhibition in the CNS. Front Mol Neurosci. 2015;8:51–56.
   PubMed Web of Science ®Google Scholar
• Fernández-Suárez D, Krapacher FA, Andersson A, et al. MAG induces apoptosis in cerebellar granule neurons through p75NTR demarcating granule layer/white matter boundary. Cell Death Dis. 2019;10(10):732.
   PubMed Web of Science ®Google Scholar
• Jin S-G, Ryu H-H, Li S-Y, et al. Nogo-A inhibits the migration and invasion of human malignant glioma U87MG cells. Oncol Rep. 2016;35(6):3395–3402.
   PubMed Web of Science ®Google Scholar
• Marucci G, Di Oto E, Farnedi A, et al. Nogo-A: a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion. Hum Pathol. 2012;43(3):374–380.
   PubMed Web of Science ®Google Scholar
• Jung T-Y, Jung S, Lee K-H, et al. Nogo-A expression in oligodendroglial tumors. Neuropathology. 2011;31(1):11–19.
   PubMed Web of Science ®Google Scholar
• Kuhlmann T, Gutenberg A, Schulten H-J, et al. Nogo-A expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas? Am J Surg Pathol. 2008;32(10):1444–1453.
   PubMed Web of Science ®Google Scholar
• Koper OM, Kamińska J, Milewska A, et al. The isoform A of reticulon-4 (Nogo-A) in cerebrospinal fluid of primary brain tumor patients: influencing factors. Oncotarget. 2018;9:25048–25056.
   PubMedGoogle Scholar
• Liao H, Duka T, Teng FYH, et al. Nogo-66 and myelin-associated glycoprotein (MAG) inhibit the adhesion and migration of nogo-66 receptor expressing human glioma cells. J Neurochem. 2004;90(5):1156–1162.
   PubMed Web of Science ®Google Scholar
• Cebral J, Ollikainen E, Chung BJ, et al. Flow conditions in the intracranial aneurysm lumen are associated with inflammation and degenerative changes of the aneurysm wall. AJNR Am J Neuroradiol. 2017;38(1):119–126.
   PubMed Web of Science ®Google Scholar
• Kamińska J, Lyson T, Chrzanowski R, et al. Ratio of IL-8 in CSF versus serum is elevated in patients with unruptured brain aneurysm. J Clin Med. 2020;9(6):1761.
   PubMed Web of Science ®Google Scholar
• Koper OM, Kamińska J, Sawicki K, et al. Cerebrospinal fluid and serum IL-8, CCL2, and ICAM-1 concentrations in astrocytic brain tumor patients. Ir J Med Sci. 2018;187(3):767–775.
   PubMed Web of Science ®Google Scholar
• Shan G. Improved confidence intervals for the youden index. PLoS One. 2015;10(7):e0127272.
   PubMed Web of Science ®Google Scholar
• Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Casp J Intern Med. 2013;4:627–635. http://www.ncbi.nlm.nih.gov/pubmed/24009950.
   PubMedGoogle Scholar
• Lai C-Y, Tian L, Schisterman EF. Exact confidence interval estimation for the youden index and its corresponding optimal cut-point. Comput Stat Data Anal. 2012;56(5):1103–1114.
   PubMed Web of Science ®Google Scholar
• Villa C, Miquel C, Mosses D, et al. The 2016 world health organization classification of tumours of the Central nervous system. Presse Med. 2018;47(11–12 Part 2):e187–e200.
   PubMed Web of Science ®Google Scholar
• Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol. 2013;125(5):621–636.
   PubMed Web of Science ®Google Scholar
• Mikol DD, Alexakos MJ, Bayley CA, et al. Structure and chromosomal localization of the gene for the oligodendrocyte-myelin glycoprotein. J Cell Biol. 1990;111(6 Part 1):2673–2679.
   PubMed Web of Science ®Google Scholar
• Buss A, Sellhaus B, Wolmsley A, et al. Expression pattern of NOGO-A protein in the human nervous system. Acta Neuropathol. 2005;110(2):113–119.
   PubMed Web of Science ®Google Scholar
• Hao C-Q, Zhou Y, Wang J-P, et al. Role of Nogo-A in the regulation of hepatocellular carcinoma SMMC7721 cell apoptosis . Mol Med Rep. 2014;9(5):1743–1748.
   PubMed Web of Science ®Google Scholar
• Bolboacă SD. Medical diagnostic tests: a review of test anatomy, phases, and statistical treatment of data. Comput Math Methods Med. 2019;2019:1891569–1891522.
   PubMed Web of Science ®Google Scholar
• Parikh R, Mathai A, Parikh S, et al. Understanding and using sensitivity, specificity and predictive values. Indian J Ophthalmol. 2008;56(1):45–50.
   PubMed Web of Science ®Google Scholar
• Trevethan R. Sensitivity, specificity, and predictive values: Foundations, pliabilities, and pitfalls in research and practice. Front Public Health. 2017; 5:307.
   PubMed Web of Science ®Google Scholar
• Wagner PL, Austin F, Sathaiah M, et al. Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin. Ann Surg Oncol. 2013;20(2):506–514.
   PubMed Web of Science ®Google Scholar